194 related articles for article (PubMed ID: 24957163)
1. Long-term results of a phase II trial with frontline concurrent chemoradiotherapy followed by consolidation chemotherapy for localized nasal natural killer/T-cell lymphoma.
Tsai HJ; Lin SF; Chen CC; Chen TY; Su WC; Hwang WL; Lin JC; Chiou TJ; Kao WY; Chiu CF; Chang YF; Chang JS; Chang MC; Su IJ
Eur J Haematol; 2015 Feb; 94(2):130-7. PubMed ID: 24957163
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study.
Kim SJ; Kim K; Kim BS; Kim CY; Suh C; Huh J; Lee SW; Kim JS; Cho J; Lee GW; Kang KM; Eom HS; Pyo HR; Ahn YC; Ko YH; Kim WS
J Clin Oncol; 2009 Dec; 27(35):6027-32. PubMed ID: 19884539
[TBL] [Abstract][Full Text] [Related]
3. Concurrent Chemoradiation Therapy Followed by Consolidation Chemotherapy for Localized Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type.
Oh D; Ahn YC; Kim SJ; Kim WS; Ko YH
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):677-83. PubMed ID: 26461010
[TBL] [Abstract][Full Text] [Related]
4. Concurrent Etoposide, Steroid, High-dose Ara-C and Platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal type.
Michot JM; Mazeron R; Danu A; Lazarovici J; Ghez D; Antosikova A; Willekens C; Chamseddine AN; Minard V; Dartigues P; Bosq J; Carde P; Koscielny S; De Botton S; Ferme C; Girinsky T; Ribrag V
Eur J Cancer; 2015 Nov; 51(16):2386-95. PubMed ID: 26254810
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008).
Yoon DH; Kim SJ; Jeong SH; Shin DY; Bae SH; Hong J; Park SK; Yhim HY; Yang DH; Lee H; Kang HJ; Lee MH; Eom HS; Kwak JY; Lee JH; Suh C; Kim WS
Oncotarget; 2016 Dec; 7(51):85584-85591. PubMed ID: 27542213
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes of upfront concurrent chemoradiotherapy followed by P-GDP regimen in newly diagnosed early stage extranodal nasal-type NK/T cell lymphoma: A prospective single-center phase II study.
Zhu F; Liu T; Pan H; Xiao Y; Li Q; Liu X; Chen W; Wu G; Zhang L
Medicine (Baltimore); 2020 Aug; 99(33):e21705. PubMed ID: 32872045
[TBL] [Abstract][Full Text] [Related]
7. Concurrent IMRT and weekly cisplatin followed by GDP chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell lymphoma.
Ke QH; Zhou SQ; Du W; Liang G; Lei Y; Luo F
Blood Cancer J; 2014 Dec; 4(12):e267. PubMed ID: 25501024
[TBL] [Abstract][Full Text] [Related]
8. A phase II prospective study of the "Sandwich" protocol, L-asparaginase, cisplatin, dexamethasone and etoposide chemotherapy combined with concurrent radiation and cisplatin, in newly diagnosed, I/II stage, nasal type, extranodal natural killer/T-cell lymphoma.
Jiang M; Zhang L; Xie L; Zhang H; Jiang Y; Liu WP; Zhang WY; Tian R; Deng YT; Zhao S; Zou LQ
Oncotarget; 2017 Jul; 8(30):50155-50163. PubMed ID: 28404973
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211.
Yamaguchi M; Tobinai K; Oguchi M; Ishizuka N; Kobayashi Y; Isobe Y; Ishizawa K; Maseki N; Itoh K; Usui N; Wasada I; Kinoshita T; Ohshima K; Matsuno Y; Terauchi T; Nawano S; Ishikura S; Kagami Y; Hotta T; Oshimi K
J Clin Oncol; 2009 Nov; 27(33):5594-600. PubMed ID: 19805668
[TBL] [Abstract][Full Text] [Related]
10. Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study.
Kim SJ; Yang DH; Kim JS; Kwak JY; Eom HS; Hong DS; Won JH; Lee JH; Yoon DH; Cho J; Nam TK; Lee SW; Ahn YC; Suh C; Kim WS
Ann Hematol; 2014 Nov; 93(11):1895-901. PubMed ID: 24947798
[TBL] [Abstract][Full Text] [Related]
11. Pegaspargase Combined with Concurrent Radiotherapy for Early-Stage Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Two-Center Phase II Study.
Wang H; Wang L; Li C; Wuxiao Z; Chen G; Luo W; Lu Y
Oncologist; 2020 Nov; 25(11):e1725-e1731. PubMed ID: 32627928
[TBL] [Abstract][Full Text] [Related]
12. [Concurrent chemoradiotherapy followed by consolidation chemotherapy and sequential chemoradiotherapy for stage III non-small cell lung cancer: comparison in 93 patients].
Sun WZ; Song LP; Zhang YB; Ai T; Lu JL; Ren J; Gao Y
Nan Fang Yi Ke Da Xue Xue Bao; 2012 Mar; 32(3):362-7. PubMed ID: 22445984
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study.
Yamaguchi M; Kwong YL; Kim WS; Maeda Y; Hashimoto C; Suh C; Izutsu K; Ishida F; Isobe Y; Sueoka E; Suzumiya J; Kodama T; Kimura H; Hyo R; Nakamura S; Oshimi K; Suzuki R
J Clin Oncol; 2011 Nov; 29(33):4410-6. PubMed ID: 21990393
[TBL] [Abstract][Full Text] [Related]
14. Trial of LVDP regimen (L-asparaginase, etoposide, dexamethasone, and cisplatin, followed by radiotherapy) as first-line treatment for newly diagnosed, stage III/IV extranodal natural killer/T cell lymphoma.
Wang YQ; Yang Y; Zhuo HY; Zou LQ; Jiang Y; Jiang M
Med Oncol; 2015 Feb; 32(2):435. PubMed ID: 25572807
[TBL] [Abstract][Full Text] [Related]
15. Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy.
Guo Y; Lu JJ; Ma X; Wang B; Hong X; Li X; Li J
Oral Oncol; 2008 Jan; 44(1):23-30. PubMed ID: 17306611
[TBL] [Abstract][Full Text] [Related]
16. Intensity-modulated radiation therapy followed by GDP chemotherapy for newly diagnosed stage I/II extranodal natural killer/T cell lymphoma, nasal type.
Huang Y; Yang J; Liu P; Zhou S; Gui L; He X; Qin Y; Zhang C; Yang S; Xing P; Sun Y; Shi Y
Ann Hematol; 2017 Sep; 96(9):1477-1483. PubMed ID: 28695246
[TBL] [Abstract][Full Text] [Related]
17. Phase 2 trial of "sandwich" L-asparaginase, vincristine, and prednisone chemotherapy with radiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/T-cell lymphoma.
Jiang M; Zhang H; Jiang Y; Yang Q; Xie L; Liu W; Zhang W; Ji X; Li P; Chen N; Zhao S; Wang F; Zou L
Cancer; 2012 Jul; 118(13):3294-301. PubMed ID: 22139825
[TBL] [Abstract][Full Text] [Related]
18. A comparison of treatment modalities for nasal extranodal natural killer/T-cell lymphoma in early stages: The efficacy of CHOP regimen based concurrent chemoradiotherapy.
Cao J; Lan S; Shen L; Si H; Zhang N; Li H; Guo R
Oncotarget; 2017 Mar; 8(12):20362-20370. PubMed ID: 27901491
[TBL] [Abstract][Full Text] [Related]
19. Retrospective analysis of treatment outcomes for extranodal NK/T-cell lymphoma (ENKL), nasal type, stage I-IIE: single institute experience of combined modality treatment for early localized nasal extranodal NK/T-cell lymphoma (ENKL).
Lee J; Cho SG; Chung SM; Ryu MR; Kim SH; Jang HS; Choi BO
Ann Hematol; 2013 Mar; 92(3):333-43. PubMed ID: 23180438
[TBL] [Abstract][Full Text] [Related]
20. Prospective pilot study of consolidation chemotherapy with docetaxel and cisplatin after concurrent chemoradiotherapy for advanced head and neck cancer.
Lee KC; Lee SH; Lee Y; Park SH; Park J; Cho EK; Shin DB; Lee JH; Kim DY; Kim ST
Int J Radiat Oncol Biol Phys; 2008 May; 71(1):187-91. PubMed ID: 17996392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
